Body Blow

Body blow    Last Friday the US Food and Drug Administration (FDA) delivered a body blow to the near-term ambitions of Australian biotech hopeful, Mesoblast, with its decision to issue a Complete Response Letter (CRL) for the company’s treatment for pediatric patients with steroid-refractory graft versus host disease (GVHD), Remestemcel-L. Read more…